NCCI Flags Tariff-Driven WC Medical Equipment Cost Acceleration in April 2026 Report

From tracking NCCI's quarterly Medical Inflation Insights series since its launch, the April 2026 edition stands out for one reason: it marks the first time NCCI has explicitly flagged tariff-related cost pressures as a potential driver of workers compensation medical price acceleration. The report's observation that medical equipment and supply prices accelerated in early 2026 and that this "may be one of the first signs of tariff-related impacts on prices in these categories" should prompt every pricing actuary working on WC loss cost filings to revisit their medical severity trend assumptions at the component level. A composite trend that blends accelerating equipment costs with declining pharmaceutical prices will mask the divergence that matters most for prospective rate adequacy.

~3.5%

Hospital outpatient annualized price trend, consistent with longer-term pace (NCCI April 2026)

+6%

WC medical lost-time claim severity increase, AY 2024 (NCCI AIS 2025)

86%

WC calendar year 2024 combined ratio, 8th consecutive year below 90 (NCCI)

What the April 2026 WCWMI Report Actually Says

NCCI's Medical Inflation Insights series publishes quarterly and tracks how Bureau of Labor Statistics price indices are flowing through to workers compensation medical spending. The April 2026 edition covers data through March 2026 and delivers three headline findings that pricing actuaries need to decompose individually rather than average together.

Hospital outpatient care. Price growth moderated in early 2026 compared with a year ago. More recent monthly increases have been consistent with the longer-term annualized trend of around 3.5%. Given that hospital outpatient services represent approximately 27% of WC medical spending according to NCCI's Medical Call data, a moderating trend in this category pulls the composite index lower. The 3.5% pace is materially below the 5% to 6% range observed during the post-pandemic period, and if sustained would represent a return to pre-2022 trend levels for the single largest WC medical cost category.

Medical equipment and supplies. Prices accelerated in early 2026, and NCCI flagged this as potentially "one of the first signs of tariff-related impacts on prices in these categories." Durable medical equipment accounts for roughly 15% of WC medical spending, a share large enough that tariff-driven acceleration in this component can offset moderation in other categories. The acceleration is consistent with broader supply chain signals: Section 301 duties of 25% on Chinese-origin medical devices, plus a Section 232 national security investigation covering everything from surgical robots to syringes, have created a layered tariff regime where effective duty rates on some imported components now exceed 40%.

Pharmaceutical prices. Drug prices declined in early 2026, which NCCI attributed to "several federal government initiatives to keep prices contained." The Inflation Reduction Act's Medicare drug negotiation provisions, expanded Medicaid rebate requirements, and state-level formulary management are all contributing to downward pressure. For WC pricing, however, pharmaceutical reimbursement follows CPI-based indices rather than PPI, and the share of WC medical spending on drugs has been declining as states tighten formulary controls and expand evidence-based treatment guidelines.

The net result: the WCWMI's first-quarter pace came in below its 2024 and 2025 trend, but NCCI's report explicitly cautioned that this moderate pace "is unlikely to be sustained" and that the index is expected to trend closer to its 2024 and 2025 levels later in the year. If hospital outpatient monthly increases continue at 3.5% and the WCWMI follows, the composite index would approach 2.5%, a level that pricing actuaries need to evaluate against the 6% medical severity increase NCCI reported for accident year 2024 at AIS 2025.

How the WCWMI Is Constructed: A Pricing Actuary's Guide

The Workers Compensation Weighted Medical Price Index is not simply CPI medical or PPI medical relabeled. Understanding its construction is essential for any actuary selecting medical severity trend factors, because the WCWMI deliberately reweights BLS price indices to match the actual distribution of medical spending observed in workers compensation claims rather than the general healthcare economy.

NCCI builds the WCWMI using methodology similar to the Bureau of Economic Analysis Personal Health Care (PHC) price index but substitutes NCCI's proprietary Medical Call data for the PHC's economy-wide healthcare spending weights. The Medical Call captures all reported medical transactions across 38 NCCI member states, giving the organization direct visibility into where WC medical dollars flow.

The index construction uses different BLS source indices depending on the spending category:

WC Medical Category	Approx. Share of WC Medical Spend	BLS Source Index	Q1 2026 Direction
Physician services	~40%	PPI (offices of physicians)	Stable
Hospital outpatient	~27%	PPI (general medical/surgical hospitals, outpatient)	Moderating toward 3.5%
Durable medical equipment	~15%	CPI (medical equipment and supplies)	Accelerating (tariff-flagged)
Prescription drugs	Declining share	CPI (prescription drugs)	Declining
Long-term care (home health, skilled nursing)	Remainder	Mixed CPI/PPI	Stable to modest increase

Two design choices matter for trend selection. First, physician and hospital services use PPI rather than CPI as their proxy. The PPI is more expansive than CPI for healthcare, incorporating price changes paid by all payer types, including Medicare and Medicaid, not just consumer out-of-pocket costs. Because WC reimbursement in most states is tied to fee schedules that reference Medicare rates or state-specific conversion factors, the PPI better captures the price dynamics facing WC payers. Second, drugs and medical equipment use CPI because WC reimbursement for these categories generally tracks consumer-facing prices more closely than provider-level prices.

This bifurcation matters in 2026 because consumer-paid medical costs (CPI medical) outpaced producer-paid medical costs (PPI medical) in early 2026, a divergence NCCI flagged as warranting continued monitoring. When the CPI-sourced components (drugs, equipment) diverge from the PPI-sourced components (physicians, hospitals), the composite WCWMI can move differently from either CPI medical or PPI medical alone. Pricing actuaries who benchmark medical severity trend to headline CPI medical or PPI medical without adjusting for the WC-specific weighting will miss this divergence.

Why PPI Over CPI for WC Medical Benchmarking

The CPI versus PPI medical divergence in early 2026 reinforces a principle that experienced WC pricing actuaries already know: CPI medical reflects what consumers pay out of pocket, while PPI medical reflects what providers receive from all payers. WC fee schedules are structured as provider reimbursement rates, not consumer cost-sharing arrangements. When CPI medical runs ahead of PPI medical, as it did in Q1 2026, using CPI medical as the trend benchmark will overstate the actual price pressure on WC claims for the physician and hospital components. The WCWMI's mixed-source approach handles this correctly, but actuaries building bespoke trend assumptions should follow the same logic: PPI for provider-reimbursed categories, CPI for patient-purchased categories.

Tariff Transmission: From Import Duties to WC Fee Schedules

The pathway from federal tariff policy to workers compensation claim costs runs through multiple intermediaries, and each one introduces lags and friction that pricing actuaries must account for when projecting medical severity trends.

The current tariff regime affecting medical equipment operates on three layers. Section 301 tariffs impose 25% duties on Chinese-origin medical devices and components. The Section 122 tariff adds 15% on top for certain categories. And a Section 232 national security investigation, launched in early 2026, covers the full range of durable medical devices, consumable supplies, and personal protective equipment. For Chinese-origin goods, these duties stack: effective rates on some orthopedic implants, surgical instruments, and rehabilitation equipment now exceed 40%.

The transmission to WC claim costs follows a multi-step chain:

Step 1: Import price increase. Tariffs raise the landed cost of imported medical devices, components, and raw materials (titanium, specialty plastics, semiconductors used in diagnostic equipment). The BLS Import Price Index for medical goods captures this first-order effect, and it is the earliest available leading indicator for pricing actuaries tracking tariff transmission.

Step 2: Manufacturer pass-through. Domestic manufacturers absorb some cost increases and pass through others. The PPI for Medical Equipment and Supplies Manufacturing (BLS series PCU33913391) captures the producer-level price change. Historical patterns suggest manufacturers pass through 60% to 80% of tariff costs within six to twelve months, with the remainder absorbed through supply chain adjustments or margin compression.

Step 3: Fee schedule adjustment. WC fee schedules in most states update annually or semi-annually. States using Medicare-referenced reimbursement will see changes flow through the CMS fee schedule update cycle, which in 2026 reflects a 2.7% Medicare Economic Index increase. States with independent fee schedules, like Texas (conversion factor $72.07 for 2026) and South Carolina ($52.00 effective April 2026), set their own rates based on a mix of CMS inputs and state-specific cost data. The lag between tariff imposition and fee schedule adjustment is typically 12 to 24 months.

Step 4: Claim cost emergence. Even after fee schedules adjust, the claim cost impact depends on treatment mix. A WC claim requiring a knee replacement with an imported titanium implant will see materially different tariff exposure than a claim treated with physical therapy and domestic pharmaceuticals. NCCI's Medical Call data captures these treatment patterns, which is precisely why the WCWMI's WC-specific weighting matters more than a generic medical inflation benchmark.

The critical timing implication: tariffs imposed in early 2025 and escalated through early 2026 are just now beginning to appear in the CPI equipment and supplies series. The full pass-through to WC fee schedules and claim costs will continue emerging through 2027. Pricing actuaries selecting prospective medical severity trends for loss cost filings effective in late 2026 and 2027 need to anticipate the pipeline, not just react to the data in hand.

Component-Level Trend Selection Under Divergence

When individual components of the WCWMI move in opposite directions, the standard approach of selecting a single composite medical severity trend and applying it uniformly across all medical cost categories breaks down. The April 2026 data presents exactly this scenario: equipment costs accelerating, pharmaceutical costs declining, and hospital outpatient costs moderating. A single composite trend will either overstate the drug component or understate the equipment component.

The component-level approach begins with decomposing historical medical severity into the same categories used by the WCWMI, then selecting separate trend factors for each component weighted by the carrier's own treatment mix.

Hospital outpatient (27% weight). With monthly price increases running at the 3.5% annualized pace and NCCI projecting the WCWMI to trend back toward 2.5%, a selected trend in the 3.0% to 4.0% range is defensible for prospective periods, with the midpoint reflecting a continuation of current monthly momentum and the upper end reflecting the NCCI caution that the moderate Q1 pace may not be sustained.

Physician services (40% weight). PPI for physician offices has been relatively stable. A trend selection in the 2.5% to 3.5% range aligns with fee schedule update cycles and Medicare conversion factor adjustments. States with active fee schedule reform may see different trajectories, and state-specific adjustments should override national trend where credible data exists.

Medical equipment and supplies (15% weight). This is where the tariff-driven divergence concentrates. A prospective trend in the 5% to 8% range acknowledges the acceleration NCCI flagged, the tariff pipeline still flowing through to producer and consumer prices, and the 12-to-24-month lag before fee schedule adjustments fully absorb the cost increase. Actuaries should stress-test this component under three tariff scenarios:

Tariff rollback scenario (lower bound): Section 301 medical device tariffs are reduced or suspended within 12 months, equipment price trend reverts to 2% to 3%. Apply 20% credibility weight.
Status quo scenario (central estimate): Current tariff levels persist through 2027, equipment price trend runs 5% to 6% with partial manufacturer absorption. Apply 50% credibility weight.
Escalation scenario (upper bound): Section 232 investigation results in additional duties of 10% to 25% on broad medical device categories by mid-2027, equipment price trend reaches 7% to 9%. Apply 30% credibility weight.

Pharmaceuticals (declining share). Federal pricing initiatives and state formulary tightening support a negative-to-flat trend in the near term. A selected trend of -1% to +1% reflects the tension between downward regulatory pressure and potential tariff exposure if pharmaceutical tariff proposals advance beyond the current investigation stage.

The credibility-weighted composite medical severity trend becomes:

Composite trend = (0.40 x physician trend) + (0.27 x hospital outpatient trend) + (0.15 x equipment trend) + (0.18 x pharma/other trend)

Using the midpoints of each range under the status quo tariff scenario: (0.40 x 3.0%) + (0.27 x 3.5%) + (0.15 x 5.5%) + (0.18 x 0.0%) = 1.20% + 0.95% + 0.83% + 0.00% = 2.97%. Under the escalation scenario with equipment trend at 8%: the composite rises to 3.35%. The difference of 0.38 percentage points may appear small, but compounded over a three-year prospective period on a $10 billion WC premium base, it translates to roughly $115 million in cumulative loss cost impact.

How Medical Severity Trend Feeds Into Loss Cost Filings

NCCI's loss cost filing process incorporates medical severity trend as one component within the broader trend factor applied to historical experience data. The filing formula projects historical losses forward to the prospective period using composite trend factors that combine frequency trend, indemnity severity trend, and medical severity trend. Each component is selected based on the most recent data available, and medical severity trend is where the WCWMI's quarterly updates provide direct input.

The relationship between WCWMI movements and filed loss cost changes is not one-to-one. A state loss cost filing reflects the net effect of frequency changes (which have been declining at approximately 5% annually), indemnity severity changes (+6% in AY 2024), medical severity changes (+6% in AY 2024), benefit level changes (state-specific legislative adjustments), and loss development factor updates. A filing can show a net decrease even when medical severity trend is positive, because declining frequency and favorable loss development can more than offset the severity increase.

This is precisely the dynamic that has produced consecutive years of WC loss cost decreases in most NCCI states. But the trend is shifting. NCCI's preview of the 2026 State of the Line noted that the 2025 to 2026 filing cycle showed the smallest count of loss cost decreases since 2018, signaling that the margin between favorable frequency and adverse severity is narrowing. If medical equipment cost acceleration adds 0.3 to 0.4 points to the composite medical trend while frequency declines moderate, the arithmetic that has supported WC profitability at an 86% combined ratio begins to tighten.

Pricing actuaries should be especially attentive to the filing lag. Loss cost filings typically use two full policy years of experience. A filing prepared in mid-2026 with an effective date of January 2027 will incorporate medical severity data through 2024 or early 2025, meaning the tariff-driven equipment cost acceleration observed in early 2026 will not yet appear in the historical experience. The prospective trend factor is the only mechanism to capture this forward-looking cost pressure, and it requires the actuary to look beyond the historical data and incorporate external indicators like the WCWMI's component-level breakdown, PPI medical equipment series, and import price indices.

Leading Indicators for Prospective Trend Selection

Pricing actuaries who want to stay ahead of the medical severity curve should build a monitoring framework around four leading indicators that capture tariff-driven cost pressure before it appears in WC claim data.

BLS PPI Medical Equipment and Supplies Manufacturing (PCU33913391). This monthly series tracks producer-level prices for domestic medical equipment manufacturing. It captures tariff pass-through from both domestic producers facing higher input costs and the competitive pricing umbrella that import tariffs create. A sustained move above the 2% to 3% historical range would signal that the acceleration NCCI flagged is broadening from imported goods to the domestic supply base.

BLS Import Price Index for medical goods. The most direct measure of tariff impact, this index captures the landed cost of imported medical devices and supplies before domestic markup. Movements in this series lead PPI medical equipment by three to six months and WC claim cost emergence by 12 to 18 months.

NCCI WCWMI quarterly updates. Each quarterly release provides the freshest composite and component-level data calibrated to WC-specific spending weights. Patterns we have tracked in the series show that sustained acceleration in any single component typically takes two quarters to fully flow through to the composite index, meaning the April 2026 equipment acceleration flagged here will be confirmed or contradicted by the July 2026 release.

Federal tariff schedule announcements. The Commerce Department's Section 232 investigation on medical devices is required to submit findings within 270 months of launch, with potential tariff actions following in summer 2027. Any interim actions, exclusion decisions, or escalation announcements will provide direct signal on the magnitude and duration of the tariff cost layer.

Why This Matters

Workers compensation has delivered an 86% combined ratio for the eighth consecutive year, with $16 billion in estimated industry reserve redundancy. That performance has been built on declining claim frequency, moderate medical inflation, and a decade of cumulative rate decreases that have returned premium to policyholders. The system is working as intended.

But the margin is narrower than the headline suggests. Medical severity is running at +6% annually. Frequency declines are moderating. Loss cost filings are approaching flat territory. And now tariff-driven cost pressures are introducing a new variable into the medical severity equation that has no historical precedent in the WC system.

The pricing actuary's job is to recognize that the moderate Q1 2026 WCWMI reading is not the trend to select for prospective loss cost calculations. NCCI itself has told us as much. The component-level decomposition, especially the equipment cost acceleration that may be "one of the first signs of tariff-related impacts," demands a granular approach to medical severity trend selection. Blending the signal with declining drug prices in a single composite number would repeat the mistake of using headline CPI when PPI better matches the WC reimbursement structure.

With AIS 2026 opening in Orlando on May 11 and Donna Glenn's State of the Line report expected to address economic impacts including tariffs, pricing actuaries will soon have additional data to calibrate their assumptions. In the meantime, the April 2026 Medical Inflation Insights report provides enough signal to justify revisiting medical severity trend selections, building tariff scenario analysis into loss cost filing exhibits, and monitoring the PPI and import price leading indicators that will confirm whether Q1 2026 was an early warning or a one-quarter anomaly.